CellaVision AB (publ) (C26.F)
- Previous Close
14.52 - Open
15.38 - Bid 17.80 x --
- Ask 18.26 x --
- Day's Range
15.38 - 17.34 - 52 Week Range
13.10 - 25.95 - Volume
733 - Avg. Volume
95 - Market Cap (intraday)
403.548M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
31.11 - EPS (TTM)
0.54 - Earnings Date Jul 17, 2025
- Forward Dividend & Yield 0.22 (1.52%)
- Ex-Dividend Date May 7, 2025
- 1y Target Est
--
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers, instruments; and hardware products include in vitro diagnostics IVD for laboratories; as well as its portfolio includes smear makers, stainers, stains, and staining protocols; DIFF-Line is a hematology lab that handles a smaller amount daily blood samples and consists three instruments for smearing, staining, and analyzing peripheral blood smears CellaVision DC-1, RAL SmearBox, and RAL StainBox. It also provides CellaVision DC-1 for performing blood cell differentials; CellaVision DM1200 and CellaVision DM9600 are designed to automate and simplify the process of performing blood and body fluid differentials. In addition, its CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
www.cellavision.comRecent News: C26.F
View MorePerformance Overview: C26.F
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: C26.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: C26.F
View MoreValuation Measures
Market Cap
348.78M
Enterprise Value
337.65M
Trailing P/E
27.10
Forward P/E
23.26
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.27
Price/Book (mrq)
4.67
Enterprise Value/Revenue
5.14
Enterprise Value/EBITDA
16.92
Financial Highlights
Profitability and Income Statement
Profit Margin
19.46%
Return on Assets (ttm)
11.44%
Return on Equity (ttm)
18.37%
Revenue (ttm)
723.22M
Net Income Avi to Common (ttm)
140.72M
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
149.43M
Total Debt/Equity (mrq)
3.29%
Levered Free Cash Flow (ttm)
75.51M